Eric Aguiar - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Eric Aguiar has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Profile
Eric Aguiar serves as Director of BridgeBio Pharma, Inc. (BBIO). Aguiar has also held reporting roles at Biomea Fusion, Inc. (BMEA). Aguiar has reported 4 insider filings with the SEC since 2025. The most recent filing was in June 2026.
| Role | Director |
|---|---|
| Notability | 26/100 |
Board memberships
- BridgeBio Pharma, Inc.
- Biomea Fusion, Inc.
Reported roles
- Director
Trading Pattern
InsiderAlpha's records for Eric Aguiar go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Eric Aguiar has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at BridgeBio Pharma, Inc. (BBIO) - 1 filing, 2026
- Insider at Biomea Fusion, Inc. (BMEA) - 2 filings, 2025 to 2026
- Insider at BridgeBio Pharma, Inc. (BBIO) - 1 filing, 2025
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | BBIO | BridgeBio Pharma, Inc. | A - Grant or award | 4.0K | $0.00 | |
| 2025-06-20 | BBIO | BridgeBio Pharma, Inc. | A - Grant or award | 6.6K | $0.00 |
Companies - Last 90 Days
- BridgeBio Pharma, Inc. (BBIO) - 1 filing, last 2026-06-24
- Biomea Fusion, Inc. (BMEA) - 1 filing, last 2026-06-12
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Eric Aguiar has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Neil Kumar - $54.29M of BBIO open-market activity in the last 12 months
- Jennifer E. Cook - $21.92M of BBIO open-market activity in the last 12 months
- Frank McCormick - $17.25M of BBIO open-market activity in the last 12 months
- Charles J. Homcy - $13.91M of BBIO open-market activity in the last 12 months
- Andrea Ellis - $6.49M of BBIO open-market activity in the last 12 months
- Andrew Lo - $6.32M of BBIO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Fairmount Funds Management LLC
- Scott Farquhar
- Tilman J. Fertitta
- James E. Flynn
- Framework Ventures IV L.P.
- Angeliki Frangou
- Spencer Frazier
- Paul J. Fribourg
Frequently Asked Questions
Who is Eric Aguiar?
Eric Aguiar serves as Director of BridgeBio Pharma, Inc. (BBIO). Aguiar has also held reporting roles at Biomea Fusion, Inc. (BMEA). Aguiar has reported 4 insider filings with the SEC since 2025. The most recent filing was in June 2026.…
How many SEC Form 4 filings has Eric Aguiar submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Eric Aguiar's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Eric Aguiar profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.